Cargando…
Cancer cell reprogramming: a promising therapy converting malignancy to benignity
In the past decade, remarkable progress has been made in reprogramming terminally differentiated somatic cells and cancer cells into induced pluripotent cells and cancer cells with benign phenotypes. Recent studies have explored various approaches to induce reprogramming from one cell type to anothe...
Autores principales: | Gong, Lanqi, Yan, Qian, Zhang, Yu, Fang, Xiaona, Liu, Beilei, Guan, Xinyuan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6716904/ https://www.ncbi.nlm.nih.gov/pubmed/31464654 http://dx.doi.org/10.1186/s40880-019-0393-5 |
Ejemplares similares
-
C-terminal truncated HBx initiates hepatocarcinogenesis by downregulating TXNIP and reprogramming glucose metabolism
por: Zhang, Yu, et al.
Publicado: (2020) -
Correction: C-terminal truncated HBx initiates hepatocarcinogenesis by downregulating TXNIP and reprogramming glucose metabolism
por: Zhang, Yu, et al.
Publicado: (2021) -
Inhibition of lysyl oxidase‐like 2 overcomes adhesion‐dependent drug resistance in the collagen‐enriched liver cancer microenvironment
por: Gong, Lanqi, et al.
Publicado: (2022) -
Targeting TROY-mediated P85a/AKT/TBX3 signaling attenuates tumor stemness and elevates treatment response in hepatocellular carcinoma
por: Liu, Beilei, et al.
Publicado: (2022) -
Dietary reprogram of macrophages for cell competition: a promising strategy for malignant cancer control
por: Chen, Jian, et al.
Publicado: (2023)